Genmab Financials - Benzinga

Genmab AS

GMABNASDAQ

Trade with Public

Trade with Public

$33.87

-0.49-1.43%

Last update: Aug 26, 10:13 AM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Genmab Financials

Genmab (GMAB) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Genmab Raises FY2026 Sales Guidance from $4.065B-$4.395B to $4.325B-$4.525B vs $4.355B Est

Genmab (NASDAQ:GMAB) raises FY2026 sales outlook from $4.065 billion-$4.395 billion to $4.325 billion-$4.525 billion vs $4.355 billion estimate.

Benzinga Newsdesk

PRO
Genmab Affirms FY2026 Sales Guidance of $4.065B-$4.395B vs $4.300B Est

Genmab (NASDAQ:GMAB) affirms FY2026 sales outlook from $4.065 billion-$4.395 billion to $4.065 billion-$4.395 billion vs $4.300 billion estimate.

Benzinga Newsdesk

PRO
Genmab Q1 EPADS $0.083 Misses $0.17 Estimate, Sales $896.000M Beat $890.400M Estimate

Benzinga Newsdesk

PRO
Genmab Sees FY2026 Sales $4.065B-$4.395B vs $4.214B Est

Genmab (NASDAQ:GMAB) sees FY2026 sales of $4.065 billion-$4.395 billion vs $4.214 billion analyst estimate.

Benzinga Newsdesk

PRO
Genmab Q4 EPS $0.05 Misses $0.44 Estimate, Sales $1.058B Miss $4.401B Estimate

Genmab (NASDAQ:GMAB) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.44 by 88.64 percent. This is a 94.12 percent decrease over earnings of $0.85 per share from the same

Benzinga Newsdesk

Genmab: Q4 Earnings Insights

Benzinga Insights